Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure

• Main Authors: Claudia Josa-Laorden, Ignacio Giménez-López, Charles Butcher, Marta Sánchez-Marteles, José Rubio-Gracia, Juan Ignacio Pérez-Calvo
• Format: Article
• Language: English
• Published: Permanyer 2021-01-01
• Series: Spanish Journal of Medicine
• Subjects: CA125. Heart failure. Prognosis. Congestion. Biomarker.
• Online Access: https://www.spanishjmed.com/frame_esp.php?id=24

Introduction and objectives: Glycoprotein carbohydrate antigen 125 (CA125) has been proposed as a new biomarker in heart failure (HF). Its potential prognostic role in chronic (CHF) and acute HF (AHF) is still underrecognized. Methods: Observational prospective study. The aims of this study were to analyze prognostic information (mortality at 1 and 12 months after discharge) yielded by serum CA125 in AHF and whether changes in concentrations from admission to discharge improved risk stratification. Results: Two hundred and four patients with AHF were included (median age 81 ± 4 years). Both CA125, at admission and discharge, were associated with short and long-term prognosis. CA125 at discharge had the greatest area under the curve (AUC) for predicting HF mortality (AUC = 0.735, 95% CI 0.54 - 0.93 p = 0.003). Moreover, CA125 above median on admission and discharge, increased the risk of long-term mortality in the multivariate study (Admission CA125: Exp[B] = 2.16; p = 0.032 and discharge CA125: Exp[B] = 3.15; p = 0.023). In addition, a rise of CA125 during admission (56% of patients) was associated with higher mortality at 12 months (p = 0.035), especially among patients with CA125 > 55UI/mL at admission. Conclusions: Concentrations of serum CA125 measured during acute decompensation of HF may help identify patients with poor prognosis after discharge. The lack of CA125 decrease during hospitalization, despite clinical improvement, is related to long-term poor outcomes.